Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor to Enhance Immune Response and Inflammation


Local inflammation processes are crucially important in the host defense against pathogens and for successful immunization because pro-inflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the strength and duration of immune responses, especially to weak antigens. The inventors have shown that adenosine receptors play a critical and non-redundant role in down-regulation of inflammation in vivo by acting as the physiological termination mechanism that can limit the immune response. The adenosine A2a and A3a receptors have been identified as playing a critical role in down-regulation of the immune response during inflammation.

This invention claims methods for inhibiting signaling through the adenosine receptor to prolong and intensify the immune response. The method involves administering either an adenosine-degrading drug or an adenosine receptor agonist. Also claimed in the invention is use of adenosine receptor agonists or adenosine-degrading drugs as vaccine adjuvants and methods for accomplishing targeted tissue damage such as for tumor destruction.

Inventors:

Michail Sitkovsky (NIAID)  ➽ more inventions...

Akio Ohta (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,080,554 issued 2011-12-20
U.S. Pat: 8,716,301 issued 2014-05-06
U.S. Pat: 9,415,105 issued 2016-08-16
US Application No. 10/498,416
US Application No. 13/310,264
US Application No. 14/067,005
US Application No. 16/391,423

Publications:
Ohta A, et al. PMID 11780065

Licensing Contact:
Yogikala Prabhu,
Email: prabhuyo@niaid.nih.gov
Phone: 301-761-7789

OTT Reference No: E-051-2002-0
Updated: Apr 2, 2015